CLRB · Cellectar Biosciences, Inc.
$2.40
-0.07 (-2.83%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$19.26M
Shares
7.99M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$21.79M
+51.1%
FY2025
Diluted EPS
-$8.35
+80.1%
FY2025
Operating Cash Flow
-$23.12M
+51.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $11.08M | $11.5M | $26.14M | $27.27M | $18.27M | $17.59M | $10.14M | $9M | $6.84M | $9.47M | $4.75M | $5.16M | $5.96M | $6.86M | $5.12M | $3.6M | $2.98M | — | — | — | — | — | — | — | |
| $11.29M | $11.48M | $25.64M | $11.69M | $10.55M | $6.54M | $5.15M | $5.18M | $4.82M | $4.14M | $4.7M | $3.4M | $3.7M | $4.44M | $3.63M | $2.69M | $1.16M | — | — | — | — | — | — | — | |
| — | $213.6K | $291.65K | $192.38K | $148.44K | $149.92K | $141.45K | $132.8K | $82.27K | $1.55M | $356.67K | $362.5K | $367.2K | $424.76K | $497.25K | $584.84K | $580.11K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $204K | — | $1.1M | — | — | — | — | — | — | — | — | — | — | |
| $22.37M | $22.98M | $51.78M | $38.96M | $28.81M | $24.13M | $15.29M | $14.18M | $13.33M | $13.6M | $9.45M | $8.76M | $9.89M | $12.4M | $8.75M | $7.04M | $4.19M | — | — | — | — | — | — | — | |
| -$22.37M | -$22.98M | -$51.78M | -$38.96M | -$28.81M | -$24.13M | -$15.29M | -$14.18M | -$13.33M | -$13.6M | -$9.45M | -$8.76M | -$9.89M | -$12.4M | -$8.75M | -$7.04M | -$4.19M | — | — | — | — | — | — | — | |
| $1.53M | $1.19M | $7.26M | -$3.87M | -$3.04M | $8918 | $196.18K | $85.71K | $91.74K | $38.68K | $3.27M | $3.26M | $1.84M | $1.62M | -$42.19K | -$397.7K | -$366.58K | — | — | — | — | — | — | — | |
| — | -$21.79M | -$44.52M | -$42.83M | -$31.85M | -$24.12M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $66K | -$60K | -$60K | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.11M | — | — | — | — | — | — | — | — | |
| -$20.84M | -$21.79M | -$44.58M | -$37.98M | -$31.79M | -$24.12M | -$15.09M | -$14.09M | -$13.24M | -$13.56M | -$6.18M | -$5.5M | -$8.05M | -$10.78M | -$8.8M | -$7.44M | -$4.56M | -$6.22M | -$6.09M | -$5.09M | -$963.44K | -$481.84K | -$342.76K | -$295.79K | |
| — | — | — | — | — | — | — | -$14.09M | -$15.48M | -$15.01M | -$9.36M | — | — | -$51.6M | -$9.34M | -$7.44M | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$8.35 | -$36.52 | -$105.00 | -$135.30 | -$130.50 | -$228.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$8.35 | -$41.89 | -$105.00 | -$135.30 | -$130.50 | -$552.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.61M | 1.22M | 407.39K | 235.19K | 185.05K | 66.04K | 25.58K | 9873.24 | 4677.1067 | 14.56K | 2606.5833 | 1530.8867 | 9315.19 | 137.07K | 79.86K | — | — | — | — | — | — | — | — |
| shares | — | 2.61M | 1.24M | 407.39K | 235.19K | 185.05K | 66.04K | 25.58K | 9873.24 | 4677.1067 | 14.56K | 2606.5833 | 1530.8867 | 9315.19 | 137.07K | 79.86K | — | — | — | — | — | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2013: $31.67K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×